Creo Medical Group Statistics

Total Valuation

AIM:CREO has a market cap or net worth of GBP 59.87 million. The enterprise value is 55.57 million.

Market Cap	59.87M
Enterprise Value	55.57M

Important Dates

The last earnings date was Monday, May 12, 2025.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

AIM:CREO has 402.47 million shares outstanding. The number of shares has increased by 37.81% in one year.

Current Share Class	402.47M
Shares Outstanding	402.47M
Shares Change (YoY)	+37.81%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	5.30%
Owned by Institutions (%)	88.33%
Float	360.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	14.97
PB Ratio	1.41
P/TBV Ratio	1.42
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.94
EV / Sales	13.89
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.47

Financial Position

The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.10.

Current Ratio	2.75
Quick Ratio	0.60
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	-0.20
Interest Coverage	-69.25

Financial Efficiency

Return on equity (ROE) is -54.40% and return on invested capital (ROIC) is -30.13%.

Return on Equity (ROE)	-54.40%
Return on Assets (ROA)	-24.45%
Return on Invested Capital (ROIC)	-30.13%
Return on Capital Employed (ROCE)	-62.25%
Revenue Per Employee	31,008
Profits Per Employee	-222,481
Employee Count	287
Asset Turnover	0.06
Inventory Turnover	0.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -58.68% in the last 52 weeks. The beta is 0.55, so AIM:CREO's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	-58.68%
50-Day Moving Average	11.66
200-Day Moving Average	17.69
Relative Strength Index (RSI)	62.39
Average Volume (20 Days)	2,471,951

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AIM:CREO had revenue of GBP 4.00 million and -28.70 million in losses. Loss per share was -0.08.

Revenue	4.00M
Gross Profit	1.90M
Operating Income	-27.70M
Pretax Income	-29.00M
Net Income	-28.70M
EBITDA	-26.70M
EBIT	-27.70M
Loss Per Share	-0.08

Full Income Statement

Balance Sheet

The company has 8.70 million in cash and 4.40 million in debt, giving a net cash position of 4.30 million or 0.01 per share.

Cash & Cash Equivalents	8.70M
Total Debt	4.40M
Net Cash	4.30M
Net Cash Per Share	0.01
Equity (Book Value)	42.40M
Book Value Per Share	0.11
Working Capital	35.90M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -22.20 million and capital expenditures -300,000, giving a free cash flow of -22.50 million.

Operating Cash Flow	-22.20M
Capital Expenditures	-300,000
Free Cash Flow	-22.50M
FCF Per Share	-0.06

Full Cash Flow Statement

Margins

Gross Margin	47.50%
Operating Margin	-692.50%
Pretax Margin	-725.00%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

AIM:CREO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-37.81%
Shareholder Yield	n/a
Earnings Yield	-47.94%
FCF Yield	-37.58%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AIM:CREO has an Altman Z-Score of -1.54. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.54
Piotroski F-Score	n/a